The effects of selenium administration on carotid intima-media thickness and metabolic status in diabetic hemodialysis patients: A randomized, double-blind, placebo-controlled trial

Salimian, Marzieh; Soleimani, Alireza; Bahmani, Fereshteh; Tabatabaei, S M; Asemi, Zatollah; Talari, Hamid Reza

doi:10.1016/j.clnesp.2021.11.022

Cited by 11 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a significant increase was observed for the parameters of insulin sensitivity, HDL-cholesterol and total glutathione. Overall, the selenium supplementation improved the general metabolic status in HD diabetic patients [ 151 ].…”

Section: Cardiovascular Diseasementioning

confidence: 99%

The Role of Selenium in Pathologies: An Updated Review

2022

View full text Add to dashboard Cite

Selenium is an essential microelement required for a number of biological functions. Selenium—and more specifically the amino acid selenocysteine—is present in at least 25 human selenoproteins involved in a wide variety of essential biological functions, ranging from the regulation of reactive oxygen species (ROS) concentration to the biosynthesis of hormones. These processes also play a central role in preventing and modulating the clinical outcome of several diseases, including cancer, diabetes, Alzheimer’s disease, mental disorders, cardiovascular disorders, fertility impairments, inflammation, and infections (including SARS-CoV-2). Over the past years, a number of studies focusing on the relationship between selenium and such pathologies have been reported. Generally, an adequate selenium nutritional state—and in some cases selenium supplementation—have been related to improved prognostic outcome and reduced risk of developing several diseases. On the other hand, supra-nutritional levels might have adverse effects. The results of recent studies focusing on these topics are summarized and discussed in this review, with particular emphasis on advances achieved in the last decade.

show abstract

Section: Cardiovascular Diseasementioning

confidence: 99%

The Role of Selenium in Pathologies: An Updated Review

2022

View full text Add to dashboard Cite

show abstract

“…Then, 2530 studies were retained after excluding 2160 duplicates, and a further 2503 studies were eliminated after reading the title and abstract, leaving 27 studies that met the screening criteria for full-text evaluation. Finally, 10 RCTs [30,[41][42][43][44][45][46][47][48][49] were included in this meta-analysis. The screening process is depicted in Figure 1.…”

Section: Literature Selectionmentioning

confidence: 99%

“…In the included studies, the forms of selenium supplementation were mainly selenium yeast and sodium selenite, but three studies did not mention the form of selenium supplementation. Five studies [37,41,43,45,48] recruited patients with diabetes mellitus or complications of diabetes mellitus (e.g., diabetic nephropathy), three studies [30,42,44] recruited patients with cardiovascular disease, one study [46] recruited patients with diabetes mellitus combined with coronary heart disease, and one study [49] recruited obese patients (Table 1).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…All of the 10 studies were rated as carrying a low risk of performance bias and concealment bias due to complete reporting of blinding implementation. Eight studies [30,41,42,[44][45][46][47]49] were rated as having a low risk of attrition bias, but Najib 2020 [43] and Faghihi 2014 [48] were rated as high risk due to unbalanced and unexplained loss at follow-up. Farrokhian 2016 [46] and Alizadeh 2012 [49] were rated as high risk of reporting bias because the primary outcomes were changed after the protocol registration.…”

Section: Risk Of Bias Assessmentsmentioning

confidence: 99%

“…Farrokhian 2016 [46] and Alizadeh 2012 [49] were rated as high risk of reporting bias because the primary outcomes were changed after the protocol registration. Due to the lack of a registered protocol [48] or the inability to report several secondary outcomes [41][42][43]45], five studies were rated as unknown risks of report bias. Farrokhian 2016 [45] was rated a high risk of other bias because of the inconsistency in the types of hypoglycemic drugs taken between the selenium and control groups, which may have affected the effect evaluation (Figures 2 and 3).…”

Section: Risk Of Bias Assessmentsmentioning

confidence: 99%

See 2 more Smart Citations

Potential Benefits of Selenium Supplementation in Reducing Insulin Resistance in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Background: Selenium is a trace element that has been reported to be effective in regulating glucose and lipid metabolism. However, there is conflicting evidence from different clinical trials of selenium supplementation in treating cardiometabolic diseases (CMDs). Objective: This meta-analysis aimed to identify the effects of selenium supplementation on insulin resistance, glucose homeostasis, and lipid profiles in patients with CMDs. Methods: Randomized controlled trials (RCTs) of selenium supplementation for treating CMDs were screened in five electronic databases. Insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR), fasting plasma glucose (FPG), and glycosylated hemoglobin A1C (HbA1c) were defined as the primary outcome markers, and lipid profiles were considered the secondary outcome markers. Results: Ten studies involving 526 participants were included in the meta-analysis. The results suggested that selenium supplementation significantly reduced serum insulin levels (standardized men difference [SMD]: −0.53; 95% confidence interval [CI] [−0.84, −0.21], p = 0.001, I2 = 68%) and HOMA-IR (SMD: −0.50, 95% CI [−0.86, −0.14], p = 0.006, I2 = 75%) and increased high-density lipoprotein cholesterol (HDL-C) levels (SMD: 0.97; 95% CI [0.26, 1.68], p = 0.007, I2 = 92%), but had no significant effect on FPG, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein cholesterol (VLDL-C). Conclusion: Current evidence supports the beneficial effects of selenium supplementation on reducing insulin levels, HOMA-IR, and increasing HDL-C levels. Selenium supplementation may be an effective strategy for reducing insulin resistance in patients with CMDs. However, more high-quality clinical studies are needed to improve the certainty of our estimates.

show abstract